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Abstract 
Background: Although pregnancy rate in in vitro fertilization-embryo transfer 
(IVF-ET) cycles has been increased over the preceding years, but the majority of 
IVF-ET cycles still fail. Granulocyte colony stimulating factor (GCSF) is a 
glycoprotein that stimulates cytokine growth factor and induces immune system 
which may improve pregnancy rate in women with history of implantation failure. 
Objective: The aim of this study was to evaluate GCSF ability to improve 
pregnancy rate in women with history of implantation failure 
Materials and Methods: 0.5 ml (300 µg/ml) GCSF was infused intrauterine in 
intervention group. Pregnancy outcomes were assessed based on clinical pregnancy. 
Results: The mean age of participants was 31.95±4.71 years old. There were no 
significant differences between demographic characteristics in two groups 
(p>0.05). The pregnancy outcome in GCSF group was improved significantly 
(p=0.043). 
Conclusion: GCSF can improve pregnancy outcome in patients with history of 
implantation failure. 
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Introduction 
 
lthough both subclinical and clinical 
pregnancy losses occur, the majority 
of failed IVF-ET cycles exhibit lack of 
implantation. Implantation failure may occur 
repeatedly. These patients are challenges for 
the infertility specialist (1, 2). Endometrial 
function and receptive endometrium are 
essential for implantation (3, 4). Repeated 
implantation failure (RIF) was defined as 
pregnancy failure after 2-6 times with at least 
10 high quality embryos transferred into the 
uterus (5).  
About 40% of IVF cycles will be failed 
following one IVF cycle. IVF Failure is caused 
by either failure in early stage of implantation 
or early abortion. Major causes of IVF failure 
may be related to embryo quality and 
implantation failure (6-11). Granulocyte colony 
stimulating factor (GCSF) is synthesized in the 
reproductive tract naturally. GCSF stimulate 
neutrophilic granulocyte proliferation and 
differentiation, which act on macrophages of 
decidual cells, and finally affect implantation 
(12-14).  
The recruitment of dendritic cells, Th-2 
cytokine secretion and activation of T 
regulatory cells are the others immune effects 
of GCSF. The cytokine increase the proportion 
of embryos that develop to the blastocyst 
stage from 30-76%. Also GCSF 
supplemented to the embryo culture medium 
improves implantation rate. Combination of 
follicular GCSF and IL-15 is an effective 
method to define oocyte component for 
successful conception in IVF/ICSI cycles (15-
17).  
Most important role of GCSF is improving 
blastocyst development, aid to embryo 
implantation and improving devolvement of 
fetus and placenta (15, 16). GCSF can be 
effective treatment in patient with history of 
implantation failure and can improve 
endometrium growth. Also GCSF may 
increase pregnancy rate especially in women 
with thin endometrium (18, 19). GCSF is a 
glycoprotein that stimulates cytokine growth 
factor inducing immune system. GCSF 
stimulates the proliferation and differentiation 
of endometrial cells by CAMP increase in 
stromal cell through paracrine and autocrine 
A 
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signaling pathways (20).  
The aim of this study was to evaluate 
GCSF ability to improve pregnancy rate in 
women with history of implantation failure. 
 
Materials and methods 
 
This randomized controlled trial (RCT) was 
performed at Yazd Research and Clinical 
Center for Infertility, Shahid Sadoughi 
University of Medical Sciences between 
October 2014 and February 2015. The study 
was approved by the Ethics Committee of 
the university. Informed written consent was 
obtained from all couples.  
Women between 20-40 yrs old with history 
of at least two implantation failures were 
included. Participants with sickle cell 
disease, chronic neutropenia, malignancy 
history, renal failure, congenital fructose 
intolerance, respiratory infection, 
endometriosis and sever male factor were 
excluded. A total of 90 eligible women were 
randomly allocated in two equal groups; 
intervention and control. The patient 
randomized by random allocation software.  
 
Treatment protocol 
The patients received 150 IU/day Gonal f 
(Serono Labratories, Aubonne, Switzerland) 
starting on day 2 and 0.25 mg cetrorelix 
(Cetrotide; Asta Medica, Frankfurt, Germany) 
administered daily when one or more follicles 
reached 13-14 mm in diameter. The doses of 
recombinant FSH have been adjusted 
according to the ovarian response for both 
groups. Urinary hCG 10000 IU (Pregnyle, NV 
Organon, Oss, Netherlands) was 
administered when at least two leading 
follicles reached a mean diameter of 17 mm 
and the serum ER2R concentration was >500 
pg/mL.  
Transvaginal oocyte retrieval was 
scheduled 36 hr after hCG injection. 45 
patients in interventional group received 
uterine infusion of 300 µg (0.5ml) 
recombinant human GCSF (300 µg, Zahravi 
Co., Tehran, Iran) by the use of IUI catheter 
after ovarian puncture under general 
anesthesia, while the standard treatment was 
continued in the 45 patients (control group) 
and did not receive GCSF treatment. 
Following oocyte retrieval, metaphase II 
oocytes were reviewed and good-quality 
embryos (Grade A: uniform or slightly uneven 
with fragmentation of <10%; Grade B: the 
blastomeres size uniform or non-uniform, 
fragmentation amount of 10-20%) were 
transferred on day 3 for all patients.  
Following embryo transfer (ET), all patients 
received Cyclogest® vaginal pessaries (Cox 
Pharmaceuticals, Barnstaple, UK) 400 mg 
twice daily until menstruation or for 8 wks 
after ET procedure in case of clinical 
pregnancy. Clinical pregnancy was defined as 
the presence of gestational sac with fetal 
heartbeat by ultrasound 4 wks following the 
ET. The implantation rate was defined as the 
ratio of gestational sac determination on 
transvaginal ultrasonography to the number of 
transferred embryos.  
 
Statistical analysis 
All of statistical analysis was done by 
SPSS 20 (SPSS, Chicago, IL). With 95% 
confidence level, power of 80%, pR1R=20%, 
pR2R=45% and the sample size=45 in each 
group was considered. The normal distribution 
of data was checked. The normal distribution 
of data was checked. Mean±SD were 
calculated for descriptive analysis. 
Independent t-test and χP2P were used. The 
statistical significances considered as p˂0.05. 
All of analyses were based on intention to 
treat analysis. 
 
Results 
 
Totally 90 patients were included in this 
study (Figure 1). The mean age of 
participants was 31.95±4.71 years old 
(32.55±4.61 in GCSF and 31.75±5.16 in 
control group). The mean of FSH level in 
third day was 7.14±4.16 in GCSF group and 
5.17±2.31 in controls. Demographic 
characteristics of participants and ART 
characteristics are shown in tables I and II 
respectively. There were no significant 
differences in female age, infertility duration, 
third day FSH, number of ART cycles, number 
of embryos and endometrial thickness 
between groups (p>0.05). The pregnancy rate 
in GCSF group was improved significantly. 
Thirteen w o m e n  (28.88%) in GCSF group 
and 6 (13.3%) in control group were clinical 
pregnant (p=0.043). 
 
Table I. demographic characteristics of participants 
Variables GCSF group Control group The significance 
Age (year) 32.55 ± 4.61 31.75 ± 5.16 0.44 
Infertility duration (year) 9.2 ± 4.31 8.6 ± 7.22 0.63 
Num of pervious failed ART 2.57 ± 1.69 3.41 ± 1.54 0.055 
Third day FSH (m IU/ml) 7.14 ± 4.16 5.17 ± 2.31 0.059 
*Data are presented as mean±SD.  # Student t-test   Basal FSH level (day 3 FSH) (IU/L)*#  
Granulocyte colony stimulating factor and recurrent implantation failure 
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Table II. Cycle characteristics of participants 
Variables GCSF group Control group p-value 
Gonal-F (IU)P*# 1791 ± 546.75 1647 ± 570.75 0.168 
Cycle duration (day)P*# 11.59 ± 2.46 10.75 ± 1.46 0.056 
Num of  retrieved oocyte P*# 11.36 ± 6.03 14.53 ± 7.34 0.029 
Num of oocyte (M II)P*# 9.6 ± 6.6 12.46 ± 6.28 0.033 
Num of embryos P*# 7.04 ± 5.71 7.02 ± 4.29 0.983 
Num of transferred embryos P*# 2.11 ± 0.77 2.35 ± 0.71 0.123 
Embryo qualityP*$    
 A 27 (61.4%) 26 (57.8%) 0.830  B 17 (38.6%) 19 (42.2%) 
Endometrial thickness in in hCG triggering day (mm) P*# 9.13 ± 1.45 8.79 ± 1.65 0.306 
Implementation rate P**# 16.67% 5.04% 0.0151 
Clinical pregnancyP**$ 13 (28.88%) 6 (13.3%) 0.043 
Data presented as mean±SD. (n=45)  $ Data presented as n (%)  # Data presented as mean±SD. 
* Comparison was done by Independent t-test.  ** The comparison was done by χ². 
 
 
Figure 1. Consort flow chart 
 
Discussion 
 
The endometrial receptivity and thickness 
play essential role in implantation phase (18, 
20, 21). Based on our study, clinical 
pregnancy rate was improved by GCSF 
intrauterine infusion on ovarian puncture day. 
similar to previous studies that indicated G-
CSF administration may have beneficial effect 
on clinical pregnancy outcome after ART our 
findings showed that intrauterine infusion 
significantly improves the clinical pregnancy 
rate (22). One of the first studies of GCSF 
was a prospective cohort study on 4 patients 
to evaluate the effect of GCSF on thin 
endometrium. These cohort findings 
represented GCSF is a new treatment of thin 
endometrium (18).  
After the pilot study Barad et al studied the 
GCSF effect on endometrium and clinical 
pregnancy rate in a parallel double blinded 
placebo-controlled clinical trial with 141 
consecutive, unselected, consenting women 
with no history of renal disease, sickle cell 
disease, or malignancy who were undergoing 
IVF, in this study GCSF does not improve 
endometrial thickness or pregnancy rate (23). 
The other study on 37 patients with thin 
endometrium demonstrated that infusion of 
GCSF improves the endometrial thickness 
(24). Eftekhar et al also in an interventional 
study on 67 infertile women showed 
although GCSF did not improve endometrial 
thickness but significantly increased the 
pregnancy rate in women with thin 
endometrium (20). But most of the previous 
studies reported the GCSF role on 
endometrial thickness improvement (24, 25). 
The useful role of GCSF on implantation was 
overlooked.  
In spite of lesser follicles and metaphase II 
oocytes in GCSF group (statistics 
significance), implantation and pregnancy rate 
were higher than control. Our study findings 
showed that clinical and chemical pregnancy 
rate were improved by GCSF intrauterine 
infusion on the day of ovarian puncture. The 
point of GCSF effect may be endometrial-
embryo interaction which should be added to 
many positive influences of GCSF such as 
effect on ovarian function, granulose cell 
function, human decidual macrophages, 
ovulation and reduction of unexplained 
repeated abortion (14, 16). The most 
important limitation of the rare studies about 
the role of GCSF on implantation was limited 
sample size but in our study this limitation 
was satisfied. Although the mechanism of 
intrauterine infusion of GCSF is not found by 
details but since intrauterine GCSF 
decreases CD16 and CD56 and also 
increases LIF significantly, so the chances of 
getting pregnant will be improved (23). As 
noted in some studies exogenous GCSF 
Enrollment 
Lost to follow-up (n= 0) 
 Discontinued intervention (n= 1) 
Follow-Up 
Allocated to intervention (n= 45) 
 Received allocated intervention (n= 45) 
Allocated to intervention (n= 45) 
 Received allocated intervention (n= 45) 
Allocation 
Assessed for eligibility (n= 114) 
Excluded (n= 24) 
 Not meeting inclusion criteria (n= 14) 
 Declined to participate (n= 10) 
Lost to follow-up (n= 0) 
 Discontinued intervention (n= 0) 
Randomized (n= 90) 
Analysed (n= 45) 
Analysis 
Analysed (n= 44) 
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intrauterine infusion as chemical and 
mechanical stimuli can improve the 
implantation and pregnancy outcomes. The 
considered mechanism is that GCSF may 
induce secretion of endogenous cytokines 
activating the endocrine pathway (14, 20, 23-
25). Although our sample size was adequate 
but there were no blinding in our study.  
 
Conclusion 
 
As a conclusion intrauterine infusion of 
GCSF in infertile women with history of 
implantation failure is an effective treatment 
and can improve the pregnancy outcome. 
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